

Get Started with Lexis® Market Tracker

To use Lexis® Market Tracker, go to the Lexis Market Tracker link on the Mergers & Acquisitions, Banking & Finance, and Securities & Capital Markets home pages in Lexis Practice Advisor®.

Ready to find and compare deal documents?

The screenshot displays the Lexis Market Tracker interface. At the top, it says "Lexis® Market Tracker POWERED BY matterhorn". There are navigation tabs for "Search" and "Transactions", and a "Manage Saved Searches & Alerts" button. Below the navigation, there are filters for "Deal Types" (Merger, Public-Private Merger, Asset, Stock, All M&A) and "Credit (Beta)". A search bar prompts the user to "Enter keywords to search full text of transaction documents" with a "New Search" button. On the left, a "Find a Field" section allows users to filter by "Popular Fields" such as Consideration Type (set to Cash), Target Industry (set to Consumer Products), Acquirer, Target, Deal Amount (with a slider set to \$6 billion), Advising Counsel, Date (with start and end date fields), Transaction Status, Acquirer and Target Summary, Basic Transaction Terms & Figures (with a slider for target enterprise value), MAE/MAC Terms, Go-Shop/No-Shop Terms, and No-Shop provision (checked Yes).

The main area shows a table of "48 Matching Transactions". The table has columns for Transaction, Consideration Type, Target Industry, No-Shop provision, and Deal Amount. The first few rows are:

Transaction	Consideration Type	Target Industry	No-Shop provision	Deal Amount
3G Capital / Burger King Holdings, Inc.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$4,000,000,000.00
Access Industries / Warner Music Group Corp.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$3,300,000,000.00
Apollo Global Management / Cedar Fair, L.P.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$2,400,000,000.00
Apollo Group, Inc. / Smart & Final, Inc.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$812,900,000.00
Apollo Tyres Ltd / Cooper Tire & Rubber Company	Cash	Consumer Products (food & household products, entertainment)	Yes	\$2,500,000,000.00
Avnet, Inc. / Bell Microproducts Inc.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$594,000,000.00
Bayer AG / Schiff Nutrition International, Inc.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$1,200,000,000.00
Brookfield Asset Management Inc. / Longview Fibre Company	Cash	Consumer Products (food & household products, entertainment)	Yes	\$2,150,000,000.00
Century Intermediate Holding Company / American Greetings Corporation	Cash	Consumer Products (food & household products, entertainment)	Yes	\$878,000,000.00
Clearwater Paper Corporation / Cellu Tissue Holdings, Inc.	Cash	Consumer Products (food & household products, entertainment)	Yes	\$502,000,000.00

There are more resources to help you with Lexis Market Tracker:

[Sign in to Lexis Market Tracker.](#)

[Visit the Lexis Practice Advisor product page to view tutorials.](#)

Call 24/7 LexisNexis Customer Support 800-543-6862.

Ready to find and compare deal documents?

Get Started with Lexis® Market Tracker

Review, compare and analyze deal documents.

Lexis® Market Tracker POWERED BY **matterhorn**

Alert Notifications | Glossary | Help | Close | Feedback

Search Transactions **GlaxoSmithKline PLC / Human Genome Sciences, Inc.** Manage Saved Searches & Alerts

Transaction Overview

Acquirer Company: GlaxoSmithKline PLC
 Target Company: Human Genome Sciences, Inc.
 Transaction Date: July 16, 2012
 Status: Closed

Find a Field Enter Field Name Find Collapse All Expand All

Closing date (if closed) August 2, 2012

Transaction status

Transaction agreement or tender offer materially amended subsequent to announcement	Yes
Transaction pending, closed or cancelled	Closed

Valuation and consideration

Value at announcement	
Target enterprise value at announcement	\$3,000,000,000
Target equity value at announcement	\$3,600,000,000
Value at closing (if closed)	
Target enterprise value at closing	\$3,000,000,000
Target equity value at closing	\$3,600,000,000

Form of merger

Reverse	Reverse
Triangular	Triangular

Merger of equals

No	No
----	----

Consideration Type

Cash	Cash
Cash consideration (on a fully diluted basis) / common share (on a fully diluted basis)	\$14.25
Fixed or floating exchange ratio	Fixed
Floating exchange ratio calculated by VWAP	No
Promissory note or other debt instrument	No

Election of consideration by Target's shareholders

No	No
Cash election	No
Stock election	No
Mixed election	No

Transaction Documents: 1 2 3 4 5 6 7 8

Agreement and Plan of Merger (Access the original source document at www.SEC.gov)
 07/16/2012
 Agreement and Plan of Merger by and among Glaxosmithkline plc, H. Acquisition Corp. and Human Genome Sciences, Inc.

Reference: 1 2 7 of 73

AGREEMENT AND PLAN OF MERGER

This Agreement and Plan of Merger dated as of July 16, 2012 (this "Agreement"), by and among GLAXOSMITHKLINE PLC, a public limited company organized under the laws of England and Wales ("Parent"), H. ACQUISITION CORP., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and HUMAN GENOME SCIENCES, INC., a Delaware corporation (the "Company").

WHEREAS, Merger Sub has previously commenced a cash tender offer (the "Pending Offer") to purchase all of the outstanding shares of common stock, par value \$0.01 per share, of the Company (the "Company Common Stock"), together with the associated Company Rights (as defined below), for so long as such Company Rights are outstanding, subject to certain terms and conditions;

WHEREAS, the Board of Directors of Parent, Merger Sub and the Company have approved the acquisition of the Company on the terms and subject to the conditions set forth in this Agreement and, accordingly, Merger Sub has agreed to amend the Pending Offer (the Pending Offer as amended and as it may be further amended from time to time as permitted under this Agreement, the "Offer") to provide for the purchase of up to all of the outstanding shares of Company Common Stock for consideration of a price per share of Company Common Stock of \$14.25 (such amount, or any other amount per share paid pursuant to the Offer and this Agreement, the "Offer Price"), net to the seller in cash, without interest, on the terms and subject to the conditions set forth in this Agreement;

WHEREAS, following consummation of the Offer, Merger Sub will be merged with and into the Company (the "Merger"), on the terms and subject to the conditions set forth in this Agreement, with the Company surviving the Merger as a wholly-owned Subsidiary of Parent and, except as otherwise set forth herein, each share of Company Common Stock that is not tendered and accepted pursuant to the Offer will thereupon be cancelled and converted into the right to receive cash in an amount equal to the Offer Price;

WHEREAS, the Board of Directors of the Company has unanimously (i) determined that the Offer, the Merger, this Agreement and the other transactions contemplated hereby are fair to and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement, including the Offer and the Merger, and (iii) resolved to recommend that the stockholders of the Company tender their shares of Company Common Stock pursuant to the Offer and, to the extent required by applicable Law, approve the Merger and this Agreement;

WHEREAS, the Board of Directors of Merger Sub has unanimously (i) determined that the Offer, the Merger, this Agreement and the other